$ASMB

Assembly Biosciences (ASMB) began a Phase 2 trial for ABI-6250, an oral drug for chronic hepatitis D. The study will assess safety and efficacy in 80 participants, with initial data expected in Q4 2027. ABI-6250 is a once-daily oral alternative to the current injectable treatment. Gilead (GILD) has an option to license ABI-6250 if Phase 2 results are positive.

Assembly Biosciences (ASMB) will present Phase 1a data for ABI-6250 at The Liver Meeting 2026. The data shows safety, tolerability, and target engagement, with plans to advance to Phase 2 studies for chronic HDV infection and cholestatic liver diseases. ABI-6250 is an oral NTCP inhibitor. The company aims to initiate Phase 2 studies in Q4 2026 and Q1 2027.

Assembly Biosciences (ASMB) stock rose 4.9% after hours. The company opted into a 40% share of U.S. profits for its herpes drug program with Gilead Sciences. ASMB could receive $280M in milestones and royalties. The move was driven by company-specific news, not broader market trends. ASMB's cash runway extends into 2029, with a $75M payment from Gilead expected in Q4 2026.

Assembly Biosciences (ASMB) shares rose 4.9% after-hours after exercising an option to share 40% of U.S. profits from its HSV HPI program with Gilead (GILD). The program includes GS-1179, expected to enter Phase 2 trials by late 2026. Assembly Bio could receive up to $280M in milestones and royalties, with a $75M payment from Gilead in Q4 2026.

ASSEMBLY BIOSCIENCES, INC. (ASMB) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 mil

Assembly Biosciences (ASMB) reported a decrease in Q1 revenue and a widening net loss. The article, sourced from Reuters and Refinitiv, provides a brief update on the company's financial performance.

Assembly Biosciences Inc. (ASMB) reported a first-quarter loss of $9.1 million, or 54 cents per share. The biotech company generated $8.2 million in revenue for the period. Despite the quarterly loss, Assembly Biosciences shares have more than doubled in value over the last 12 months, though they have seen a slight decrease of just over 8% since the beginning of the year.

Assembly Biosciences' Chief Medical Officer, Anuj Gaggar, was granted 26,000 Restricted Stock Units (RSUs) as part of his annual equity compensation. These RSUs will vest in four equal installments annually from March 29, 2027, through March 29, 2030, provided he remains with the company. This grant represents 65% of his annual equity award, with the remaining 35% contingent on stockholder approval of an increase in shares authorized under the company's 2018 stock incentive plan.

Assembly Biosciences (ASMB) has adopted a new 2026 Corporate Bonus Plan, effective January 1, 2026, designed to motivate and reward employees with performance-based cash bonuses. The plan outlines varying target bonus opportunities, up to 75% of base salary for the CEO, and distinguishes between corporate and individual objectives. Notably, the Compensation Committee also increased CEO Jason A. Okazaki’s bonus target from 60% to 65% of his base salary for fiscal 2026.

Wall Street Zen has upgraded Assembly Biosciences (NASDAQ:ASMB) from a "buy" to a "strong-buy," aligning with an overall "Moderate Buy" consensus despite mixed analyst opinions. This upgrade follows a significant beat in quarterly EPS and revenue, though negative EPS is still forecasted for the current fiscal year. The company's stock shows a market cap of $439.41 million, and institutional investors have been actively trading its shares.